WO2001040271A3 - Cancer associated antigens and uses therefor - Google Patents

Cancer associated antigens and uses therefor Download PDF

Info

Publication number
WO2001040271A3
WO2001040271A3 PCT/US2000/032750 US0032750W WO0140271A3 WO 2001040271 A3 WO2001040271 A3 WO 2001040271A3 US 0032750 W US0032750 W US 0032750W WO 0140271 A3 WO0140271 A3 WO 0140271A3
Authority
WO
WIPO (PCT)
Prior art keywords
molecules
associated antigens
cancer associated
peptides
proteins
Prior art date
Application number
PCT/US2000/032750
Other languages
French (fr)
Other versions
WO2001040271A9 (en
WO2001040271A2 (en
Inventor
Toshiro Ono
Eiichi Nakayama
Original Assignee
Ludwig Inst Cancer Res
Toshiro Ono
Eiichi Nakayama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Toshiro Ono, Eiichi Nakayama filed Critical Ludwig Inst Cancer Res
Priority to AU19396/01A priority Critical patent/AU1939601A/en
Priority to US10/148,641 priority patent/US20040086852A1/en
Priority to EP00982348A priority patent/EP1238281A2/en
Priority to JP2001541026A priority patent/JP2003516734A/en
Publication of WO2001040271A2 publication Critical patent/WO2001040271A2/en
Publication of WO2001040271A3 publication Critical patent/WO2001040271A3/en
Publication of WO2001040271A9 publication Critical patent/WO2001040271A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in methylcholanthrene-induced fibrosarcoma cancer cells using antisera from mice bearing such tumors. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in mice afflicted with methylcholanthrene-induced fibrosarcomas, as well as homologs thereof, particularly human homologs. The invention provides, inter alia, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.
PCT/US2000/032750 1999-12-01 2000-12-01 Cancer associated antigens and uses therefor WO2001040271A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU19396/01A AU1939601A (en) 1999-12-01 2000-12-01 Cancer associated antigens and uses therefor
US10/148,641 US20040086852A1 (en) 2000-12-01 2000-12-01 Cancer associated antigens and uses therefor
EP00982348A EP1238281A2 (en) 1999-12-01 2000-12-01 Cancer associated antigens and uses therefor
JP2001541026A JP2003516734A (en) 1999-12-01 2000-12-01 Cancer-associated antigens and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16835399P 1999-12-01 1999-12-01
US60/168,353 1999-12-01
US55901300A 2000-04-26 2000-04-26
US09/559,013 2000-04-26

Publications (3)

Publication Number Publication Date
WO2001040271A2 WO2001040271A2 (en) 2001-06-07
WO2001040271A3 true WO2001040271A3 (en) 2002-04-18
WO2001040271A9 WO2001040271A9 (en) 2002-05-23

Family

ID=26864039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/032750 WO2001040271A2 (en) 1999-12-01 2000-12-01 Cancer associated antigens and uses therefor

Country Status (4)

Country Link
EP (1) EP1238281A2 (en)
JP (1) JP2003516734A (en)
AU (1) AU1939601A (en)
WO (1) WO2001040271A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450692A1 (en) * 2001-06-12 2003-01-30 Kyogo Itoh Tumor antigen
US20050221350A1 (en) 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
EP2336779B1 (en) 2004-02-19 2013-07-31 Yale University Kit for the identification of ovarian cancer protein biomarkers using proteomic techniques

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010577A1 (en) * 1994-09-30 1996-04-11 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor dage and uses thereof
WO1998041648A2 (en) * 1997-03-20 1998-09-24 Variagenics, Inc. Target genes for allele-specific drugs
WO1998057976A1 (en) * 1997-06-19 1998-12-23 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1999004238A2 (en) * 1997-07-15 1999-01-28 Mitotix, Inc. Reagents and methods for diagnosis and prognosis of proliferative disorders
WO1999047540A1 (en) * 1998-03-19 1999-09-23 Human Genome Sciences, Inc. 95 human secreted proteins
WO2000009709A2 (en) * 1998-08-10 2000-02-24 Incyte Pharmaceuticals, Inc. Proteases and associated proteins

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010577A1 (en) * 1994-09-30 1996-04-11 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor dage and uses thereof
WO1998041648A2 (en) * 1997-03-20 1998-09-24 Variagenics, Inc. Target genes for allele-specific drugs
WO1998057976A1 (en) * 1997-06-19 1998-12-23 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1999004238A2 (en) * 1997-07-15 1999-01-28 Mitotix, Inc. Reagents and methods for diagnosis and prognosis of proliferative disorders
WO1999047540A1 (en) * 1998-03-19 1999-09-23 Human Genome Sciences, Inc. 95 human secreted proteins
WO2000009709A2 (en) * 1998-08-10 2000-02-24 Incyte Pharmaceuticals, Inc. Proteases and associated proteins

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 23 September 1999 (1999-09-23), XP002185681 *
MANKI AKIRA ET AL: "Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia.", CANCER RESEARCH, vol. 58, no. 9, 1 May 1998 (1998-05-01), pages 1960 - 1964, XP001010552, ISSN: 0008-5472 *
MATSUTAKE T ET AL: "The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (2001 MAR 27) 98 (7) 3992-7., XP001014723 *
MONACH P A ET AL: "A UNIQUE TUMOR ANTIGEN PRODUCED BY A SINGLE AMINO ACID SUBSTITUTION", IMMUNITY,CELL PRESS,US, vol. 2, no. 1, January 1995 (1995-01-01), pages 45 - 59, XP000938737, ISSN: 1074-7613 *
ONO TOSHIRO ET AL: "Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 6, 13 March 2001 (2001-03-13), March 13, 2001, pages 3282 - 3287, XP001051648, ISSN: 0027-8424 *
UENAKA AKIKO ET AL: "Identification of a unique antigen peptide pRL1 on BALB/c RL 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 180, no. 5, 1994, pages 1599 - 1607, XP001014792, ISSN: 0022-1007 *

Also Published As

Publication number Publication date
AU1939601A (en) 2001-06-12
JP2003516734A (en) 2003-05-20
WO2001040271A9 (en) 2002-05-23
WO2001040271A2 (en) 2001-06-07
EP1238281A2 (en) 2002-09-11

Similar Documents

Publication Publication Date Title
WO2000073801A3 (en) Breast, gastric and prostate cancer associated antigens and uses therefor
WO2001053349A3 (en) Small cell lung cancer associated antigens and uses therefor
WO2000020587A3 (en) Cancer associated antigens and uses therefor
EP1005540A4 (en) Ikk-beta proteins, nucleic acids and methods
WO1999066025A3 (en) Mtbx protein and nucleic acid molecules and uses therefor
WO2000058473A3 (en) Nucleic acids including open reading frames encoding polypeptides; 'orfx'
WO2001031019A3 (en) Neisserial antigenic peptides
WO2004024750A3 (en) Cd44-binding ligands
WO2000052047A3 (en) Human dickkopf-related protein and nucleic acid molecules and uses therefor
EP1009752A4 (en) Novel molecules of the tango-77 related protein family and uses thereof
AU3217100A (en) Methods of use of a novel lysyl oxidase-related protein
WO2002086071A3 (en) Cancer-testis antigens
WO2002078526A3 (en) Cancer-testis antigens
WO2001000826A3 (en) Novel molecules of the card-related protein family and uses thereof
WO2000046236A3 (en) Novel rgs-containing molecules and uses thereof
AU6517400A (en) 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof
WO2000019988A8 (en) NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF
WO2000073509A3 (en) Molecules for diagnostics and therapeutics
WO2001025432A3 (en) Histamine receptor
WO2001040271A3 (en) Cancer associated antigens and uses therefor
WO2001040291A3 (en) Proteins and nucleic acids encoding the same
WO2000012544A3 (en) Novel irap-bp polypeptide and nucleic acid molecules and uses therefor
WO2001000874A3 (en) Cancer associated antigens and uses therefor
WO2000008045A3 (en) Novel molecules of the tango-93-related protein family and uses thereof
WO2000072021A3 (en) Cancer associated antigens and uses therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWE Wipo information: entry into national phase

Ref document number: 19396/01

Country of ref document: AU

AK Designated states

Kind code of ref document: C2

Designated state(s): AU CA CN JP KR US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

COP Corrected version of pamphlet

Free format text: PAGES 1/9-9/9, DRAWINGS, REPLACED BY NEW PAGES 1/8-8/8; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 541026

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000982348

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000982348

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10148641

Country of ref document: US